ImmunityBio, Inc.IBRXNASDAQ
Loading
Year-over-year research & development expense growth
Percentile
P79
Within normal range
vs 2Y Ago
3.1x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 19.86% |
| Q3 2025 | -8.15% |
| Q2 2025 | 14.52% |
| Q1 2025 | 36.95% |
| Q4 2024 | -30.18% |
| Q3 2024 | -1.34% |
| Q2 2024 | -4.16% |
| Q1 2024 | 3.53% |
| Q4 2023 | 6.47% |
| Q3 2023 | -8.96% |
| Q2 2023 | -32.50% |
| Q1 2023 | 49.03% |
| Q4 2022 | -21.25% |
| Q3 2022 | 14.45% |
| Q2 2022 | 14.33% |
| Q1 2022 | -0.90% |
| Q4 2021 | 5.02% |
| Q3 2021 | -8.41% |
| Q2 2021 | 30.81% |
| Q1 2021 | 103.04% |
| Q4 2020 | -43.37% |
| Q3 2020 | 8.38% |
| Q2 2020 | 20.57% |
| Q1 2020 | 107.49% |
| Q4 2019 | 9.47% |
| Q3 2019 | -8.22% |
| Q2 2019 | 4.23% |
| Q1 2019 | 0.95% |
| Q4 2018 | -14.28% |
| Q3 2018 | -0.88% |
| Q2 2018 | 4.98% |
| Q1 2018 | 16.39% |
| Q4 2017 | 8.60% |
| Q3 2017 | 14.04% |
| Q2 2017 | 4.95% |
| Q1 2017 | -2.09% |
| Q4 2016 | 12.92% |
| Q3 2016 | 30.91% |
| Q2 2016 | 29.23% |
| Q1 2016 | -3.17% |